Illumina, Inc. announced preliminary unaudited financial results for the fourth quarter and fiscal year 2024 on January 14, 2025, ahead of its presentation at the J.P. Morgan Healthcare Conference. The company reported an estimated Core Illumina constant currency revenue decline of approximately 2% for fiscal year 2024, with total reported revenue of $4.332 billion.
Preliminary non-GAAP operating margin for fiscal year 2024 was approximately 21.3%, and non-GAAP diluted EPS was projected to be in the range of $4.12 to $4.14. The company also reported a robust preliminary free cash flow of $1.07 billion for the fiscal year.
For fiscal year 2025, Illumina provided a preliminary outlook, expecting Core Illumina constant currency revenue growth in the low single digits, with reported revenue in the range of approximately $4.28 billion to $4.4 billion. Non-GAAP operating margin is projected to be around 23%, and non-GAAP diluted EPS is expected in the range of $4.50 to $4.65, signaling anticipated improvements in profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.